Page: 1
Protocol Number: IM101567
IND Number: BB-IND 9391
Ex-US Non-IND
EUDRACT Number N/A
Date: 27-Jul-2015
Clinical Protocol IM101567
A Randomized, Head -to-Head, Single -Blinded Study  to Assess Changes in the I mmune Profile 
in Response to Treatment with Subcutaneous Abatacept in Combination with Methotrexate 
versus Subcutaneous Adalimumab in Combination with Methotrexate in Adults with Early  
Rheumatoid Arthritis who are Naive to Biologic Disease -Modify ing Antirheumatic Drugs
Medical Monitor/Study Director
Alyssa Johnsen, MD, PhD
This document is the confidential and proprietary information of Bristol -Myers Squibb 
Company and its global affiliates (BMS). By reviewing this document, you agree to keep it 
confidential and to use and disclose it solely for the purpose of assessing whet her your 
organization will participate in and/or the performance of the proposed BMS -sponsor ed 
study. Any permitted disclosures will be made only on a confidential "need to know" basis 
within your organization or to your independent ethics committee(s). Any other use, 
copying, disclosure or dissemination of this information is strictly prohibited unless 
expressly authorized in writing by BMS. Any supplemental information (eg,amendments) 
that may be added to this document is also confidential and proprietar y to BMS and must 
be kept in confidence in the same manner as the contents of this document. Any person 
1.0
Approved
930091469
1.0
v

Clinical Protocol IM101567
BMS -188667 abatacept
Date: 27-Jul-2015 2who receives this document without due authorization from BMS is requested to return it 
to BMS or promptly destroy it. All other rights reserved. Refere nces to BMS in this 
protocol may apply to partners to which BMS has transferred obligations, eg,a Contract 
Research Organization (CRO).
1.0
Approved
930091469
1.0
v

Clinical Protocol IM101567
BMS -188667 abatacept
Date: 27-Jul-2015 3DOCUMENT HISTORY
Document Date of Issue Summary of Change
Original 
Protocol27-Jul-2015 Not applicable
1.0
Approved
930091469
1.0
v

Clinical Protocol IM101567
BMS -188667 abatacept
SYNOPSIS
Clinical Protocol IM101567
Protocol Title :A Randomized , Head -to-Head, Single- Blinded Study to Assess Changes in the Immune Profile in 
Response to Treatm ent with Subcutaneous Abatacept in Com bination with Methotrexate versus Subcutaneous 
Adalimumab in Com bination with Methotrexate in Adults with Early Rheum atoid Arthritis who are Naive to 
Biologic Disease -Modifying Antirheumatic Drugs
Investigational Product(s), Dose and Mode of Adm inistration, Duration of Treatment with Investigational 
Product(s):
Subjects will receive investigational products for a period of 24 w eeks. In this protocol, investigational products are:
abatacept subcutaneous (SC) injection, 125mg/pre -filled syringe (125 mg/mL)
adalimumab (Humira®) SCinjection, 40 mg/prefilled syringe (40 mg/0.8 mL) 
Study Phase: IV
 
 
 
 
Objectives :
Primary Objective:
Not Applicable
Secondary Objective:
Not Applicable
 
 
 
 
 
   
 
 
 
 
 
 
Date: 27-Jul-2015 4
1.0
Approved
930091469
1.0
v

Clinical Protocol IM101567
BMS -188667 abatacept
 
Study Design :See schematic below  for study design.
Screening Period:
Eligibility will be based on specified inclusion and exclusion criteria, medical history , disease activity and safety 
assessments. Randomization must occur within 28 days of signing the informed consent. Subjects that experience an 
acute infection or initiate treatment for latent TB may extend the screening period to 42 days
Treatment Period (Day 1 -Week 24):
On Day 1, subjects w ill be randomized to one of two parallel treatment arms in a 1:1 ratio: 
1.Abatacept SC (125 mg) weekly 
2.Adalimu mab SC (40 mg) once every two weeks
The Treatment Period duration is 24 w eeks.
Abatacept and adalimumab a dministration :
On Day 1, subjects and/or personal caregivers will be trained in self administration of SC injections using pre-filled 
syringes. 
Methotrexate:
Subjects must have been treated with oral methotrexate for at least 12 weeks prior to randomization with a stable 
dose for at least 28 day s prior to random ization. The stable dose of oral m ethotrexate should be a m inimum  targeted 
Date: 27-Jul-2015 5
1.0
Approved
930091469
1.0
v

Clinical Protocol IM101567
BMS -188667 abatacept
dose of at least 20 mg weekly. A dose of methotrexate < 20 mg/week but 7.5 mg/week is permitted if intolerance to 
higher doses has been recorded in the source documents.
The dose of methotrexate must remain stable throughout the study, and may only be lowered due to intolerance or 
adverse event . Should intolerance occur and the dose of methotrexate requires reduction, subjects must stay on the 
lower methotrexate dose for the remainder of the study.
Parenteral administration of methotrexate is not perm itted at any time during the study. All subjects must receive 
folic acid, folinic acid, or leucovorin according to the manufacturer’s recommendations.
Post-Treatment Follow -up Period:
Subjects who discontinue treatm ent of study drug or complete the study will have one follow -up visit 85 days after 
the last dose of investigational product to perform safety assessme nts.. 
Study Population :Men or women (not nursing or pregnant) years old who have early RA, defined as 
diagnosed with RAby ACR/EULAR 2010 classification (Appendix 1)and have hadsymptoms of RA for no more 
than 9 months prior to signing the informed consent. Symptom s of RA are defined as pain, stiffness or swelling in 
joints which are typically inflamed in RA. Subjects who had a single isolated episode of palindromic symptoms that 
occurred less than 2 years prior to enrollment are still eligible. Subjects must have asecond generation anti-cyclic 
citrullinated peptide (anti-CCP2 )test result that is greater than 3-times the upper limit of norm al and berheumatoid 
factor (RF)positive at screening according to central laboratory testing. Subjects must have a DAS28CRP 
(Appendix 2) at screening and have at least 3 tender and at least 3 swollen joints (excluding distal 
interphalangeal s) at screening and at randomization.
Eligible subjects must have been treated with oral methotrexate for at least 12weeks prior to randomization with a 
stable dose for at least 28 days prior to randomization. The stable dose of oral methotrexate should be aminimu m 
targeted dose of at least 20 mg w eekly, unless the dose of methotrexate was limited by intolerance, in which case 7.5 
mg is the minimum required dose.
Investigational [Medicinal] Products (IP/IMP) a re as listed:
IP/IMP Potency 
Abatacept SCinjection 125mg/pre- filled syringe (125 mg/mL)
Adalimumab SC injection 40 mg/prefilled syringe (40 mg/0.8 mL)
Study Assessments :See Section 5 of the protocol for detailed information regarding study assessments.
Statistical Considerations :
Sample Size: In this study 25 subjects will be randomized per treatment arm.
 
 
 
 
 
            
 
 
Date: 27-Jul-2015 6
1.0
Approved
930091469
1.0
v

Clinical Protocol IM101567
BMS -188667 abatacept

 
 
 
 
 
 
 
 
Date: 27-Jul-2015 7
1.0
Approved
930091469
1.0
v

TABLE OF CONTENTS 
TITLE PAGE ................................................................................................................ 
DOCUMENT HISTORY .............................................................................................. SYNOPSIS .................................................................................................................... TABLE OF CONTENTS .............................................................................................. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2 ETHICAL CONSIDERATIONS ............................................................................... 
2.1 Good Clinical Practice ...................................................................................... 2.2 Institutional Review Board/Independent Ethics Committee ............................. 2.3 Informed Consent.............................................................................................. 
3 INVESTIGATIONAL PLAN .................................................................................... 
3.1 Study Design and Duration ............................................................................... 
3.1.1 Screening Period ...................................................................................... 3.1.2 Treatment Period (Day 1 to Week 24) ..................................................... 3.1.3 Post-Treatment Follow-up Period ........................................................... 
3.2 Post Study Access to Therapy ........................................................................... 3.3 Study Population ............................................................................................... 
3.3.1 Inclusion Criteria ..................................................................................... 3.3.2 Exclusion Criteria .................................................................................... 3.3.3 Women of Childbearing Potential ........................................................... 
 
 
 
 
 
 
 
 
3.5 Discontinuation of Subjects following any Treatment with Study Drug .......... 
3.6 Post Study Drug Study Follow up .................................................................... 
3.6.1 Withdrawal of Consent ............................................................................ 3.6.2 Lost to Follow-Up .................................................................................... 13
4
8
1213
13
14
14
14
14
14
14
1515
15
16
17
18
18
19
19
20
20
21
22
22
23
23
23
25
28
29
29
29
29
31
31
31
31
32
32
33
33Clinical Protocol
BMS-188667IM101567
abatacept
Date: 27-Jul-2015 8
1.0
Approved
930091469
1.0
v

4 STUDY DRUG .......................................................................................................... 
4.1 Investigational Product ..................................................................................... 
4.2 Non-investigational Product ............................................................................. 4.3 Storage and Dispensing..................................................................................... 4.4 Method of Assigning Subject Identification ..................................................... 4.5 Selection and Timing of Dose for Each Subject ............................................... 
4.5.1 Abatacept Treatment Arm ........................................................................ 
4.5.1.1 Self-Administration of Subcutaneous Injection ............................... 4.5.1.2 Administration Window .................................................................. 4.5.1.3 Dose Modifications ......................................................................... 
4.5.2 Adalimumab Treatment Arm .................................................................... 
4.5.2.1 Self-Administration of Subcutaneous Injection ............................... 4.5.2.2 Administration Window .................................................................. 4.5.2.3 Dose Modifications ......................................................................... 
4.5.3 Guidelines for Methotrexate .................................................................... 
4.6 Blinding/Unblinding ......................................................................................... 4.7 Treatment Compliance ...................................................................................... 4.8 Destruction of Study Drug ................................................................................ 4.9 Return of Study Drug ........................................................................................ 
5 STUDY ASSESSMENTS AND PROCEDURES ..................................................... 
5.1 Flow Chart/Time and Events Schedule ............................................................. 
5.1.1 Retesting During Screening, Extended Screening, or Rescreening ......... 5.1.2 Order of Study Assessments ..................................................................... 
5.2 Study Materials ................................................................................................. 5.3 Safety Assessments ........................................................................................... 
5.3.1 Physical Examination .............................................................................. 
5.3.2 Chest X-ray .............................................................................................. 
5.3.3 Physical Measurements ........................................................................... 5.3.4 Vital Signs ................................................................................................ 5.3.5 TB Screening ............................................................................................ 5.3.6 Laboratory Assessments........................................................................... 
5.3.6.1 Hematology ..................................................................................... 5.3.6.2 Blood Chemistry.............................................................................. 5.3.6.3 Urinalysis ........................................................................................ 5.3.6.4 Hepatitis Screen .............................................................................. 5.3.6.5 Pregnancy Tests .............................................................................. 5.3.6.6 HIV Testing ..................................................................................... 
 
 
 
 
 
 
 
 
 33
34
35
35
35
35
36
36
36
36
36
37
37
37
37
38
39
39
40
41
41
48
48
49
4950
50
50
50
50
50
51
51
51
51
52
52
52
53
53
53
53
53
54
54
54Clinical Protocol
BMS-188667IM101567
abatacept
Date: 27-Jul-2015 9
1.0
Approved
930091469
1.0
v

 
 
 
 
 
 
 
 
 
6 ADVERSE EVENTS 
................................................................................................. 
6.1 Serious Adverse Events .................................................................................... 
6.1.1 Serious Adverse Event Collection and Reporting .................................... 
6.2 Nonserious Adverse Events .............................................................................. 
6.2.1 Nonserious Adverse Event Collection and Reporting .............................. 
6.3 Laboratory Test Result Abnormalities .............................................................. 
6.4 Pregnancy .......................................................................................................... 6.5 Overdose ........................................................................................................... 6.6 Potential Drug Induced Liver Injury (DILI) ..................................................... 6.7 Other Safety Considerations ............................................................................. 
7 DATA MONITORING COMMITTEE AND OTHER EXTERNAL COMMITTEES
................................................................................................................................. 
8 STATISTICAL CONSIDERATIONS....................................................................... 
8.1 Sample Size Determination ............................................................................... 8.2 Populations for Analyses .................................................................................. 
8.3 Endpoints .......................................................................................................... 
8.3.1 Primary Endpoint(s) ................................................................................ 
8.3.2 Secondary Endpoint(s) ............................................................................. 
 
8.4 Analyses ............................................................................................................ 
8.4.1 Demographics and Baseline Characteristics........................................... 
 
8.4.3 Safety Analyses......................................................................................... 
 
 
 
 
 
9 STUDY MANAGEMENT ........................................................................................ 
9.1 Compliance ....................................................................................................... 
9.1.1 Compliance with the Protocol and Protocol Revisions ........................... 
9.1.2 Monitoring ............................................................................................... 
9.1.2.1 Source Documentation .................................................................... 
9.1.3 Investigational Site Training.................................................................... 
9.2 Records ............................................................................................................. 54
54
54
55
55
55
55
55
55
56
56
56
57
58
58
59
59
60
60
60
60
60
6060
61
61
61
61
61
61
61
62
62
62
62
62
62
63
63
63
63
64
64
64Clinical Protocol
BMS-188667IM101567
abatacept
Date: 27-Jul-2015 10
1.0
Approved
930091469
1.0
v

9.2.1 Records Retention .................................................................................... 
9.2.2 Study Drug Records ................................................................................. 9.2.3 Case Report Forms .................................................................................. 
9.3 Clinical Study Report and Publications ............................................................ 
10 GLOSSARY OF TERMS ........................................................................................ 11 LIST OF ABBREVIATIONS .................................................................................. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 64
64
65
66
67
68
72
75
76
77
78
79
80
81
84Clinical Protocol
BMS-188667IM101567
abatacept
Date: 27-Jul-2015 11
1.0
Approved
930091469
1.0
v

Clinical Protocol IM101567
BMS -188667 abatacept
 
 
 
 
 
 
  
  
 
 
    
 
 
 
 
 
 
 
 
2 ETHICA L CONSIDERA TIONS
2.1 Good Clinical Practice
This study  will be conducted in accordance with Good Clinical Practice (GCP), as defined by  the 
International Conference on Harmonisation (ICH) and in accordance with the ethical principles 
underly ing European Union Directive 2001/20/EC and the United States Code of Federal 
Regulations, Title 21, Part 50 (21CFR50).
The study  will be conducted in compliance with the protocol. The protocol and any amendments 
and the subject informed consent will receive Institutional Revi ew Board/I ndependent Ethics 
Committee (I RB/IEC) approval/favorable opinion prior to initiation of the study .
All potential serious breaches must be reported to BMS immediatel y. A serious breach is a 
breach of the conditions and principles of GCP in connect ion with the study  or the protocol, 
which is likely to affect, to a significant degree, the safet y or physical or mental integrity  of the 
subjects of the study  or the scientific value of the study .
Personnel involved in conducting this study  will be qualif ied by education, training, and 
experience t o perform their respective tasks.
This study  will not use the services of study  personnel where sanctions have been invoked or 
where there has been scientific misconduct or fraud (eg, loss of medical licensure, debarment).
Date: 27-Jul-2015 18
1.0
Approved
930091469
1.0
v

Clinical Protocol IM101567
BMS -188667 abatacept
2.2 Institutional Review  Board/Independent Ethics Committee 
Before study  initiation, the investigator must have written and dated approval/favorable opinion 
from the IRB/IEC for the protocol, consent form, subject recruitment material s 
(eg, advertisements), and any other written information to be provided to subje cts. The 
investigator or BMS should also provide the IRB/IEC with a copy of the Investigat or Brochure 
or product labeling information to be provided to subjects and an yupdates. 
The investigator or BMS should provide the IRB/IEC with reports, updates and other 
information (eg, expedited safet y reports, amendments, and administrative letters ) according to 
regulatory  requirements or institution procedures.
2.3 Informed Consent
Investigators must ensure that subjects are clearl y and fully  informed about the purpose, potential 
risks, and other critical issues regarding clinical studies in which they volunteer to participate. 
In situation s where consent cannot be given to subjec ts, their legally  acceptable representatives
(as per country  guidelines) are clearl y and fully informed about the purpose, potential risks, and 
other critical issues regarding clinical studies in which the subject volunteers to participate. 
BMS will provide the investigator with an appropriate (ie, Global or Local) sample informed 
consent form which will include all elements required by ICH, GCP and applicable regulatory 
requirements. The sample informed consent form will adhere to the ethical principles that have 
their origin in the Declaration of Helsinki.
Investigators must:
1)Provide a copy  of the consent form and written information about the study  in the language 
in which the subject is most proficient prior to clinical study  participation. The language 
must be non- technical and easily  understood. 
2) Allow time necessary  for subject or subject's legally  acceptable representative to inquire 
about the details of the study .
3)Obtain an informed consent signed and personally  dated by the subject or the subject's 
legally  acceptable representative and by the person who conducted the informed consent 
discussion. 
4)Obtain the IRB/IEC’s written approval/favorable opinion of the written informed consent 
form and any other information to be provided to the subjects, prior to the beginning of the 
study, and after any  revisions are completed for new information.
5)If informed consent is initially  given by a subject’s legall y acceptable representative or legal 
guardian, and the subject subsequently  becomes capable of maki ng and communicating his 
or herinformed consent during the study , consent must additionally  be obtained from the 
subject.
6)Revise the informed consent whenever important new information becomes available that is 
relevant to the subject's consent. The inves tigator, or a person designated by the investigator, 
should fully inform the subject or the subject's legall y acceptable representative or legal 
guardian, of all pertinent aspects of the study  and of any new information relevant to the 
Date: 27-Jul-2015 19
1.0
Approved
930091469
1.0
v

Clinical Protocol IM101567
BMS -188667 abatacept
subject's willingness to continue participation in the study . This communication should be 
documented. 
The confidentiality  of records that could identify  subjects must be protected, respecting the 
privacy  and confidentiality  rules applicable to regulatory  requirements, the subjects' signed ICF 
and, in the US, the subjects’ signed HIPAA Authorization.
The consent form must also include a statement that BMS and regulatory  authorities have direct 
access to subject records.
The rights, safet y, and well -being of the study  subjects are the most important considerations and 
should prevail over interests of science and society.
3 INVESTIGA TIONA L PLA N
3.1 Study Design and Duration
This is an exploratory , randomized, single -blinded assessment study  in subjects who have 
recentl y been diagnose d with rheumatoid arthritis according to ACR/EULAR 2010 classification
(Appendix 1),and having symptoms of RA for 9 months or less prior to screening , and have 
been on MTX for at least 12 weeks with a stable dose of MTX for at least 28 daysprior to 
randomization and are naive to biologic DMARD. It consists of a screening period of up to 28 
days, followed by  a 24 week Treatment Period, followed by  85 day  follow -up period.
The study  design schematic is presented in Figure 3.1 -1.
Date: 27-Jul-2015 20
1.0
Approved
930091469
1.0
v

Clinical Protocol IM101567
BMS -188667 abatacept
Figure 3.1 -1: Study Design Schematic
3.1.1 Screening Period 
Eligibility  will be based on specified inclusion and exclusion criteria, medical history , disease 
activity  and safet y assessments. Randomization must occur within 28 daysof signing the 
informed consent. Subjects that experience an acute infection or initiate treatment for latent TB 
may extend the screening period to 42 day s.
Eligible subjects will have been diagnosed with rheumatoid arthritis by ACR/EULAR 2010 
classification (Appendix 1) and have had symptoms of RA for no more than 9 months prior to 
signing the informed consent. Symptoms of RA are defined as pain, stiffness or swelling in joints 
which are typicall y inflamed in RA. Subjects who had a single isolated episode of palindromic 
symptoms that occurred less than 2 years prior to enrollment are stil l eligible. In order to recruit a 
cohort of subjects with similar biomarker profiles, subjects must have an anti-CCP2 test result 
that is greater than 3 -times the upper limit of normal19and be RF positive at screening according 
to central laboratory  testing. Subjects must have a DAS28CRP (Appendix 2) at screening 
and have at least 3tender and at least 3 swollen joints (excluding distal interphalangeals [DIPs]) 
at screening and at randomization.
Subjects must have been treated with oral methotrexate for at least 12 weeks prior to 
randomization with a stable dose for at least 28 days prior torandomization. The stable dose of 
oral methotrexate should be a minimum targeted dose of at least 20 mg weekl y. A dose of 
Date: 27-Jul-2015 21
1.0
Approved
930091469
1.0
v

Clinical Protocol IM101567
BMS -188667 abatacept
methotrexate < 20 mg/week but 7.5 mg/week is permitted if intolerance to higher doses has 
been recorded in the source documents.
To minimize potential methotrexate toxicity , all subjects must receive folic acid, folinic acid, or 
leucovorin according to the manufacturer recommendations, methotrexate label instructions, and 
the local medical standard of care guidelines. 
Subjects receivi ng oral corticosteroids must be on a stable dose and at the equivalent of 10mg 
prednisone daily for at least 4 weeks prior to randomization. Subjects may not have received an 
IM, IV or IA administration of a corticosteroid within 4weeks prior to random ization.
3.1.2 Treatment Period (Day 1 to Week 24)
On Day  1, subjects will be randomized to one of two parallel treatment arms in a 1:1 ratio:
1) Abatacept SC (125 mg) weekl y 
2) Adalimumab SC (40 mg) once every  two weeks 
The Treatment Period duration is 24 we eks.
Abatacept and adalimumab administration:
On Day 1, subjects and/or personal caregivers will be trained in self administration of SC 
injections using pre -filled sy ringes. 
Methotrexate:
Subjects must have been treated with oral methotrexate for at least 12 weeks prior to 
randomization with a stable dose for at least 28 days prior to randomization. The stable dose of 
oral methotrexate should be a minimum targeted dose of at least 20 mg weekl y. A dose of 
methotrexate < 20 mg/week but 7.5 mg/week is permi tted if intolerance to higher doses has 
been documented in the source documents.
The dose of methotrexate must remain stable throughout the study , and may only  be lowered due 
to intolerance or adverse event. Should intolerance occur and the dose of methotr exate requires 
reduction, subjects should stay on the lower methotrexate dose for the remainder of the study .
Parenteral administration of methotrexate is not permitted at any time during the study .All 
subjects must receive folic acid, folinic acid, or leucovorin according to the manufacturer’s 
recommendations.
3.1.3 Post-Treatment Follow- up Period
Subjects who discontinue treatment of study  drug or complete the study  will have onefollow -up
visit 85 day s after the last dose of investigational product to perform safet y assessments.
Date: 27-Jul-2015 22
1.0
Approved
930091469
1.0
v

Clinical Protocol IM101567
BMS -188667 abatacept
3.2 Post Study  Access to Therapy
At the end of the study ,BMS will not continue toprovide BMS supplied study  drug to 
subjects /investigators unless BMS chooses to extend the study . The investigator should ensure 
that the subject receives appropriate standard of care to treat the condition under study .
Treatment codes will not beprovided to the investigators after completion of the study as the 
study  drug is provided in an open- labeled fashion to sites during the study .
3.3 Study Pop ulation
For entry  into the study , the following criteria MUST be met.
3.3.1 Inclusion Criteria
1. Signed Written Informed Consent
a)Subject is willing to participate in the study  and has signed the informed consent.
2. Target Population
a)Subjects have early RA, defined as symptoms of RA that started 9 months prior to 
screening and a diagnosis made by the ACR/EULAR 2010 criteria for the classification 
of RA (Appendix 1)
b)Subjects must be naive to biologic DMARDs
c)Subjects must be naive to conventional sy nthetic DMARDs other than methotrexate
d)Subjects must be naive to targeted synthetic DMARDs25such as tofacitinib, baricitinib, 
and investigational therapies for RA .
e)Subjects must have been treated with oral methotrexate for at least 12 weeks prior to 
randomization with aminimum targeted dose of 20 mg/week methotrexate and at least 
the last 28 days being a stable dose. Subjects can be randomized if the minimum stable 
targeted dose of methotrexate is < 20mg/week but 7.5 mg/week if intolerance to higher 
doses has been do cumented in the source documents.
f)Subjects have an anti-CCP2 test that is > 3x ULN and are positive for RF according to 
central lab testing during screening.
g)Subjects must have at least aDAS28 C-reactive protein (CRP) 3.2 (Appendix 2) at 
screening.
h)Subjects must have currently  at least 3tender and at least 3swollen joints (excluding 
DIPs) at screening and atrandomization
i)Subjects receiving oral corticosteroids must be on a stable dose and at the equivalent of 
10 mg prednisone daily  for at least 4 weeks. Subjects may not receive an IM, IV or IA 
administration of a corticosteroid within 4 weeks prior to randomization.
j)Subject Re-enrollment: This study  permits the re-enrollment of a subject that has 
discontinued t he study  as a pre-treatment failure (ie, subject has not been randomized / 
has not been treated), still meets all inclusion/exclusion criteria , and no more than 
Date: 27-Jul-2015 23
1.0
Approved
930091469
1.0
v

Clinical Protocol IM101567
BMS -188667 abatacept
9months have elapsed since the onset of symptoms of RAprior to re-enrollment. If re-
enrolled, the subject must be re -consented.
3.Age and Reproductive Status
a)Men and women, ages 18 years (or age of majority )
b)Women of childbearing potential (WOCBP) must have a negative serum or urine 
pregnancy  test (minimum sensitivity  25 IU/L or equivalent units of HCG) within 
24hours prior to the start of study  drug.
c)Women must not be breastfeeding and must agree not to breastfeed during the study  and 
for 100 day s thereafter
d)WOCBP must agree to follow instructions for method(s) of contraception for the duration 
of treatment with study  drugplus 5 half-lives of study drug (70days) plus 30 days 
(duration of ovulatory  cycle) for a total of 100days post -treatment completion.
e)Males who are sexually  active with WOCBP must agree to follow instructions for 
method(s) of contraception for the duration of treatment with study  drug ,plus 5 half -lives 
of the study drug (70days) plus 90 days (duration of sperm turnover) for a total of 
160days post -treatment completion.
f)Azoospermic males and WOCBP who are continuously  not heterosexually  active are 
exempt from contraceptive requirements. However they must still undergo pregnancy  
testing as described in this section.
Investigators shall counsel WOCBP and male subjects who are sexually  active with WOCBP on 
the importance of pregnancy  prevention and the implications of an unexpected pregnancy .
Investigators shall advise WOCBP and male subjects who are sexually  active with WOCBP on 
the use of highl y effective methods of contraception. Highl y effective methods of contraception 
have a failure rate of < 1% when used consistently  and correctl y.
At a minimum, subjects must agree to the use of two methods of contraception, with one method 
being highl y effective and the other method being either highl y effective or less effective as 
listed below:
HIGHLY EFFECTIVE METHODS OF CONTRACEPTION
Male condoms with spermicide
Hormonal methods of contraception including combined oral contraceptive pills, vaginal 
ring, injectables, implants and intrauterine devices (IUDs) such as Mirenaby WOCBP 
subject or male subject’s WOCBP partner .Female partners of male subjects participating in 
the study  may use hormone based contraceptives as one of the acceptable methods of 
contraception since they  will not be receiving study  drug
Nonhormonal IUDs, such as ParaGard
Tubal ligation 
Date: 27-Jul-2015 24
1.0
Approved
930091469
1.0
v

Clinical Protocol IM101567
BMS -188667 abatacept
Vasectom y
Complete Abstinence*
*Complete abstinence is defined as complete avoidance of heterosexual intercourse and is an 
acceptable form of contraception for all study  drugs. Subjects who choose complete abstinence 
are not required to use a second method of contraception, but female subjects must continue to 
have pregnancy  tests. Acceptable alternate methods of highly  effective contraception must be 
discussed in the event that the subject chooses to forego complete abstinence .
LESS EFFECTIVE METHODS OF CONTRACEPTION
Diaphragm with spermicide
Cervical cap with spermicide
Vaginal sponge
Male Condom without spermicide 
Progestin onl y pills by WOCBP subject or male subject’s WOCBP partner 
Female Condom*
* A male and female condom must not be used together
3.3.2 Exclusion Criteria
1.Target Disease Exceptions
a)Subjects with autoimmune disease other than RA [eg, psoriasis, systemic lupus 
erythematosus (SLE), vasculitis, seronegative spondy loarthritis, Inflammatory  Bowel 
Disease, Sjogren’s s yndrome] or currentl y active fibromy algia.
b) Prior history  of or current inflammatory  joint disease other than RA (such aspsoriatic 
arthritis, gout, reactive arthritis, Ly me disease).
2.Medical History and Concurrent Diseases
a)Subjects at risk for tuberculosis (TB) defined as follows:
i)Current clinical, radiographic or laboratory  evidence of active TB. Chest x-rays 
(posterioranterior and lateral) obtained within the 3 months prior to randomization 
will be permitted but the images must be available and reviewed by the investigator. 
TB testing (IFN -release assay  or PPD) performed in the past month prior to 
Screening will be accepted; however, a copy of the report must be placed in the 
subject binder.
ii)A history  of active TB 
Date: 27-Jul-2015 25
1.0
Approved
930091469
1.0
v

Clinical Protocol IM101567
BMS -188667 abatacept
iii)Subjects with a positive TBscreening test indicative of latent TB will not be eligible 
for the stud y unless they :
(1)Have no evidence of current TB based on chest x-ray performed during the 
screening period and b y history  and ph ysical exam, and 
(2)They are activel y being treated for TB or the site has documentation of successful 
prior treatment of latent TB. Treatment regimens should be dictated by local 
guidelines as long as the treatment dose and duration meet or exceed local health 
authority  guidelines. If permitted by local guidelines regarding treatment with 
biologic medications, subjects may be randomized prior to completion of 
treatment as long as they have completed at least 4 weeks of treatment and they 
have no evidence of current TB on chest x-ray at screening. 
b)Subjects with recent acute infection defined as:
i)Any acute infection within 60 days prior to randomization that required 
hospitalization or treatment with parenteral antibiotics.
ii)Any acute infection within 30 days prior to randomizati on that required oral 
antimicrobial or antiviral therap y.
c)Subjects with history  of chronic or recurrent bacterial infection (such as chronic 
pyelonephritis, osteomy elitis, and bronchiectasis etc.).
d)Subjects with any  history of infection of a joint prosthesis or artificial joint.
e)Subjects who have a history  of systemic fungal infections (such as histoplasmosis, 
blastomy cosis, or coccidiomy cosis).
f)Subjects with history  of recurrent herpes zoster (more than 1 episode) or disseminated 
(more than 1 dermatome) herpes zoster or disseminated herpes simplex, or ophthalmic 
zoster will be excluded. Sy mptoms of herpes zoster or herpes simplex must have resolved 
more than 60 day s prior to screening.
g)Subjects with history  of Human Immunodeficiency  Virus (HIV) infection orwho test 
positive for HIV at screening.
h)Subjects with history  of primary  immunodeficiency  
i)Subjects who have present or previous malignancies, except documented history  of cured 
non-metastatic squamous or basal skin cell carcinoma, or cervical carcinoma in situ , with 
no recurrence in the 5 years prior to screening. Subjects who had screening procedure 
that is suspicious for malignancy , and in whom the possibility  of malignancy  cannot be 
reasonabl y excluded following additional clinical, laboratory  or other diagnostic 
evaluations.
j)Current clinical findings or a history  of a demy elinating disorder
k)New York Heart Association (NYHA) Class III or IV heart failure
l)Any previous or current medical conditions that are warnings against the use of TNF 
inhibitor agents .
m)Current clinical findings of severe, progressive, or uncontrolled renal, hepatic, 
hematological, gastrointestinal, pulmonary , psychiatric, cardiac, endocrine, neurological, 
Date: 27-Jul-2015 26
1.0
Approved
930091469
1.0
v

Clinical Protocol IM101567
BMS -188667 abatacept
or cerebral disease including severe and uncontrolled infections, such as sepsis and 
opportunistic infections. Concomitant medical conditions that, in the opinion of the 
investigator, might place the subject at unacceptable risk for participation in this study .
n)Subjects who have received any live vaccines within 3 months of the study  drug 
administration or are scheduled to receive live vaccines during the study . Study  subjects 
should not be administered a live virus vaccine for a minimum of 3 months following the 
last dose of study  medication. Subjects who are in close contact with others who have 
received a live vaccine may be enrolled at the investigator’s discretion.
o)Subjects who have undergone a major surgical procedure within the 60 days prior to 
randomization.
p)Subjects for whom 5 or more joints cannot be assessed for tenderness or swelling (ie due 
to surgery , fusion, amputation, etc).
q)Subjects with a history  of (within 12 months of signing informed consent), or known 
current problems with drug or alcohol abuse history  or known cirrhosis including 
alcoholic cirrhosis 
r)Subjects who are impaired, incapacitated, or incapable of completing study  related 
assessments
3. Physical and Laboratory Test Findings
a)Hepatitis B surface antigen (HBsAg) -positive, or Hepatitis B core antibody  
(HBcAb) -positive subjects with detectable hepatitis B viral D NA
b)Hepatitis C antibody  (HcAb) -positive subjects with detectable hepatitis C viral RNA
c)Hemoglobin (Hgb) < 8.5 g/dl
d)White Blood Count (WBC) < 3,000/mm3(3 x 109/L)
e)Platelets < 100,000/mm3 (100 x 109/L)
f)Serum creatinine > 2 times upper limit of normal.
g)Serum ALT or AST > 2 times upper limit of normal.
h)Evidence of active cardiac or pulmonary  disease on chest X -rays
i)Any test results that, in the opinion of the investigator, might place the subject at 
unacceptable risk for participation in this study
4.Allergies and Adverse Drug Reaction
a)Hypersensitivity  to one of the investigational products and/or its excipients.
5.Prohibited Treatments and/or Therapies
a)Subjects who have had previous exposure to abatacept or adalimumab
b)Subjects who have had previous exposure to any DMARD other than methotrexate
c)Subjects who have been exposed to any treatment with an approved or investigational 
biologic DMARD including but not limited to infliximab, etanercept, anakinra, 
Date: 27-Jul-2015 27
1.0
Approved
930091469
1.0
v

Clinical Protocol IM101567
BMS -188667 abatacept
rituximab, tocilizumab, golimumab, and certolizumab, or an investigational or approved 
targeted non- biologic DMARD, such as tofacitinib or baricitinib
d)Subjects who have received an IM, IV or IA administration of a corticosteroid within 4
weeks prior to randomization (Day  1)
e)Subjects currentl y taking NSAIDs must have been on a stable dose, as assessed by the 
Investigator, for at least 14 day s prior to randomization.
6.Other Exclusion Criteria
a)Prisoners or subjects who are involuntaril y incarcerated
b)Subjects who are compulsorily  detained for treatment of either a psychiatric or physical 
(eg, infectious disease) illness
Eligibility  criteria for this study  have been carefully  considered to ensure the safet y of thestudy 
subjects andthat the results of the study  can be used. It is imperative that subjects fully  meetall 
eligibility  criteria.
3.3.3 Women of Childbearing Potential
Women of childbearing potential (WOCBP) is defined as any female who has experienced 
menarche and who has not undergone surgical sterilization (hysterectomy  or bilateral 
oophorectom y) and is not po stmenopausal. Menopause is defined as 12 months of amenorrhea in 
a woman over age 45 years in the absence of other biological or physiological causes. In 
addition, females under the age of 55 years must have a serum follicle stimulating hormone, 
(FSH) leve l > 40mIU/mL to confirm menopause.
Females treated with hormone replacement therapy , (HRT) are likely  to have artificiall y 
suppressed FSH levels and may require a washout period in order to obtain a physiologic FSH 
level. The duration of the washout period is a function of the type of HRT used. The duration of 
the washout period below are suggested guidelines and the investigators should use their 
judgement in checking serum FSH levels. If the serum FSH level is >40 mIU/ml at any time 
during the washout pe riod, the woman can be considered postmenopausal:
1 week minimum for vaginal hormonal products (rings, creams, gels)
4 week minimum for transdermal products
8 week minimum for oral products
Other parenteral products may  require washout periods as long as 6 months.
Date: 27-Jul-2015 28
1.0
Approved
930091469
1.0
v

Clinical Protocol IM101567
BMS -188667 abatacept
 
 
 
 
 
 
 
Date: 27-Jul-2015 29
1.0
Approved
930091469
1.0
v

Clinical Protocol IM101567
BMS -188667 abatacept
 
 
 
 
 
 
 
 
 
 
 

 
 
 
 
 
 
  
 
 
Date: 27-Jul-2015 30
1.0
Approved
930091469
1.0
v

Clinical Protocol IM101567
BMS -188667 abatacept
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Date: 27-Jul-2015 31
1.0
Approved
930091469
1.0
v

Clinical Protocol IM101567
BMS -188667 abatacept
 
 
 
 
 
 
3.5 Discontinuation of Subjects follow ing any Treatment with Study Drug 
Subjects MUST discontinue investigational product (and non-investigational product at the 
discretion of the investigator) for an y of the following reasons:
Use of prohibited medication
Pregnancy
Missed Doses :
Missed greater than 6 doses of abatacept OR greater than 3 doses of adalimumab for any 
reason during the stud y
Missed greater than 4 consecutive doses of abatacept OR greater than 2 consecutive 
doses of adalimumab for any  reason during the study
Any clinical adverse event (AE), laboratory abnormality or intercurrent illness which, in the 
opinion of the investigator, indicates that continued participation in the study  is not in the 
best interest of the subject .
Subject’s request to stop study  treatment or withdrawal of informed consent
Termination of the study  by Bristol -Myers Squibb ( BMS )
Loss of abilit y to freely provide consent through imprisonment or involuntar ilyincarceration 
for treatment of either a psy chiatric or ph ysical ( eg, infectious disease) illness
All subjects who discontinue study  drugshould comply  with protocol specified follow -up 
procedures as outlined in Section 5. The only exception to this requirement is when a subject 
withdraws consent for all study  procedures including post -treatment study  follow -up or loses the 
ability  to conse nt freel y (ie, is imprisoned or involuntarily  incarcerated for the treatment of either 
a psy chiatric or ph ysical illness).
If study  drug is discontinued prior to the subject’s completion of the study , the reason for the 
discontinuation must be documented in the subject’s medical records and entered on the 
appropriate case report form (CRF) page.
3.6 Post Study  Drug Study  Follow up
Subjects who discontinue study  drug may continue to be followed. Subjects who withdraw 
consent (according to Section 3.6.1) or are lost to follow -up (according to Section 3.6.2) will not 
Date: 27-Jul-2015 32
1.0
Approved
930091469
1.0
v

Clinical Protocol IM101567
BMS -188667 abatacept
be followed in this study ; all other subjects will continue to be followed for collection of 
follow up data as required and in line with Section 5, Study  Procedures and Assessments.
3.6.1 Withdrawa l of Consent
Subjects who request to discontinue study  drug will remain in the study  and must continue to be 
followed for protocol specified follow -up procedures. The only exception to this is when a 
subject specifically  withdraws consent for any  further c ontact with him/her or persons previously 
authorized by subject to provide this informati on. Subjects should notify  the investigator of the 
decision to withdraw consent from future follow -up in writing , whenever possible. The 
withdrawal of consent should b e explained in detail in the medical records by the i nvestigator, as 
to whether the withdrawal is from further treatment with study  drug only or also from study  
procedures and/or post treatment study  follow -up, and entered on the appropriate CRF page. In 
the event that vital status (whether the subject is alive or dead) is being measured, publicly  
available information should be used to determine vital status only as appropriatel y directed in 
accordance with local law.
3.6.2 Lost to Follow -Up
All reasonable effor ts must be made to locate subjects to determine and report their ongoing 
status. This includes follow -up with persons authorized by the subjec t as noted above. Lost to 
follow -up is defined by the inability  to reach the subject after a minimum of three docu mented 
phone calls, faxes, or emails as well as lack of response by subject to one registered mail letter. 
All attempts should be documented in the subject’s medical records. If it is determined that the 
subject has died, the site will use permissible loca l methods to obtain the date and cause of death.
If investigator’s use of third- party representative to assist in the follow -up portion of the study  
has been included in the subjec t’s informed consent, then the investigator may use a 
Sponsor -retained third- party  representative to assist site staff with obtaining subject’s contact 
information or other public vital status data necessary  to complete the follow -up portion of the 
study .The site staff and representative will consult publicly  available sources, such as public 
health registries and databases, in order to obtain updated contact information. If after all 
attempts, the subject remains lost to follow -up, then the last known alive date as determined by 
the investigator should be reported and documented in the subject’s medical records .
4 STUDY DRUG
Study drugincludes both Investigational [Medicinal] Product (IP/IMP) andNon-investigational 
[Medicinal ] Product (Non-IP/Non- IMP).
Date: 27-Jul-2015 33
1.0
Approved
930091469
1.0
v

Clinical Protocol IM101567
BMS -188667 abatacept
4.1 Investigational Product
An investigational product, also known as investigational medicinal product in some regions, is defined a pharmaceutical form of an 
active substance or placebo being tested or used as a reference in a clinical study , including products alread y with a market ing 
authorization but used or assembled (formulated or packaged) different ly than the authorized form, or used for an unauthorized 
indication, or when used to gain further information about the authorized form.
The investigational product should be stored in a secure area according to local regulations. It is the responsibility  of the investigator 
to ensure that investigational product is only dispensed to study  subjects. The investigational product must be dispensed only from 
official study  sites by  authorized personnel according to local re gulations.
In this protocol, investigational products are:
Table 4.1-1: Investigation Product for IM101 -567
Product Description / 
Class and Dosage FormPotency Blinded or 
Open LabelPackaging/ Appearance Storage Conditions
(per label)
Abatacept SC injection 125 mg/prefilled syringe 
(125 mg/mL)Open label Clear to slightly opalescent, 
colorless to pale yellow 
solution, essentially free of 
particulate matter on visual 
inspectionStore refrigerated, 2 -8°C(36-46 
° F); protect from light; protect 
from freezing
Adalimumab SC injection 40 mg/prefilled syringe 
(40mg/0.8 mL)Open Label Clear; colorless solution;
essentially free of visible
particulateStore refrigerated, 2-8°C(36-46 
° F). Donot freeze . Do not use if 
frozen even if it has been thawed. 
Store inoriginal cart on until time 
of administration to protect from 
light
BMS will supply  the investigational products described above.
Date: 27-Jul-2015 34
1.0
Approved
930091469
1.0
v

Clinical Protocol IM101567
BMS -188667 abatacept
4.2 Non- investigational Product
In this protocol, non-investigational product(s) include include methotrexate, corticosteroids, 
NSAIDs, (including aspirin), folic acid, and/or folinic acid (leucovorin). BMS will not provide 
non-investigational products.
Other medications used as support or escape medication for preventative, diagnostic, or 
therapeutic reasons, as components of the standard of care for a given diagnosis, may be
considered as non-invest igational products. 
4.3 Storage and Dispensing
The product storage manager should ensure that the study  drug is stored in accordance with the 
environmental conditions (temperature, light, and humidi ty) as determined by BMS. If concerns 
regarding the qualit y or appearance of the study  drug arise, the study drug should not be 
dispensed and contact BMS immediately .
Study  drug not supplied by  BMS will be stored in accordanc e with the package insert.
Investigational product documentation (whether supplied by BMS or not) must be maintained 
that includes all processes required to ensure drug is accuratel y administered. This includes 
documentation of drug storage, administration and, as applicable, storage temperatures, 
reconstitution, and use of required processes ( eg, required diluents, administration sets).
4.4 Method of Assigning Subject Identification
At the time of enrollment, immediately  after written informed consent is obtained and before any  
study -related procedures are performed, each subject will be assigned a unique, sequential 
five-digit number beginning with 00001, 00002, 00003, and so on, for identification throughout 
the study . This subject number must not be reused f or any other subject. The study  physician or 
research coordinator must contact the Central Randomization System to enroll each subject into 
a centralized database at the time consent is obtained. 
After completion of all screening evaluations and concomita nt adjustment or stabilization, all 
eligible subjects will be randomized into the Treatment Phase of the study . Randomization 
schedules will be generated and kept by the Randomization Group within Drug Supply 
Management of Bristol -Myers Squibb. Each subjec t who qualifies for treatment will be assigned 
a unique randomization number. Randomization numbers will be assigned using a Central 
Randomization System in the order in which subjects qualif yfor treatment, not in the order of 
study  enrollment. Subjects will be randomized on a 1:1 basis to either theabatacept treatment 
arm or the adalimumab treatment arm. 
4.5 Selection and Timing of Dose for Each Subject
On “Office Visit” days, study  medication should be administered AFTER all assessments have 
been completed , including blood draws for assessment of immunogenicity  and possible drug 
concentrations .
Date: 27-Jul-2015 35
1.0
Approved
930091469
1.0
v

Clinical Protocol IM101567
BMS -188667 abatacept
4.5.1 Abatacept Treatment Arm
On Day 1, subjects will self-administer abatacept 125 mg SC from a pre-filled syringe. On 
Day 8,subjects will self-administer abatacept 125 mg SC. Thereafter, subjects will 
self-administer abatacept 125 mg SC once every  7 day s, up to and including Week 23 (Day  162).
Treatment duration is 167 days for all randomized subjects (who have not discontinued study  
therap y).
4.5.1.1 Self-Administration of Subcutaneous Injection
Each pre-filled syringe contains one weekl y dose of abatacept, 125 mg/mL . Subjects will be 
trained to self-administer their weekl y SC injection. Training should be performed by 
investigational personnel who are considered qualified trainers by the principal investigator. A 
procedure guide will be provided by BMS. The subject should be able to self-administer the 
SCinjection between office visits, or have an office -trained caregiver do so.
On office visit days, SC injections should begiven AFTER all assessments are completed, 
including blood draws. If a caregiver is responsible for giving the injections, he or she should 
accompan y the subject to office visits.
4.5.1.2 Administration Window
SC injections of study  medication may be administered 3days around the target day.The last 
dose before each office visit should be administered at least 4 days before the scheduled visit 
date. If a SC injection is not given within the administration window, the next SC injection 
should be given on the ne xt scheduled target administration day .
4.5.1.3 Dose Modifications
Dose Modifications in the Absence of Adverse Events
Subjects should complete their scheduled SC injections as described above. Subjects who miss 
the dose window should skip the SC injection and wait until the next targeted administration day .
Dose Modifications Due to Adverse Events
If abnormal laboratory  test results or clinical adverse events indicate toxicity  that, in the 
judgment of the investigator, could place the subject at risk, study  drug administration should be 
interrupted and the investigator should notify  the BMS medical monitor. Subjects may receive 
further study  medication treatment only if full resolution of the adverse event or abnormal 
laboratory  finding is documented. Under no circumstances should the dose of study drug be 
altered due to an adverse event.
4.5.2 Adalimumab Treatment Arm
Subjects randomized to adalimumab will self-administer an initial dose of adalimumab 40mg 
SC from a pre-filled syringe on Day 1. On Day 15, subjects will self-administer adalimumab 
40mg SC. Thereafter, subjects will self-administer adalimumab 40 mg SC once every  14days, 
up to and including Week 22 (Day  152). 
Date: 27-Jul-2015 36
1.0
Approved
930091469
1.0
v

Clinical Protocol IM101567
BMS -188667 abatacept
Treatment duration is 167 days for all randomized subjects (who have not discontinued study  
thera py).
4.5.2.1 Self-Administration of Subcutaneous Injection
Each pre-filled syringe contains one bi-weekl y dose of adalimumab, 40 mg/mL. Subjects will be 
trained to self-administer their bi-weekl y SC injection. Training should be performed by 
investigational person nel who are considered qualified trainers by the principal investigator. A 
procedure guide will be provided by BMS. The subject should be able to self-administer the 
SCinjection between office visits, or have an office -trained caregiver do so.
On office visit days, SC injections should be given AFTER all assessments are completed, 
including blood draws. If a caregiver is responsible for giving the injections, he or she should 
accompan y the subject to office visits.
4.5.2.2 Administration Window
SC injections of study medication may be administered 7 days around the target day.The last 
dose before each office visit should be administered at least 7days before the scheduled visit 
date. If a SC injection is not given within the administration window, the next SC injection 
should be given on the next scheduled target administration day .
4.5.2.3 Dose Modifications
Dose Modifications in the Absence of Adverse Events
Subjects should complete their scheduled SC injections as described above. In exceptional cases, 
the administration window may  be extended to 7 day s. Bey ond that, the subject should skip the 
SC injection and wait until the next targeted administration da y.
Dose Modifications Due to Adverse Events 
If abnormal laboratory  test results or clinical adverse events indicate toxicity  that, in the 
judgment of the investigator, could place the subject at risk, study  drug administration should be 
interrupted and the investigator should notify  the BMS medical monitor. Subjects may receive 
further study  medication treatment only if full resolution of the adverse event or abnormal 
laboratory  finding is documented. Under no circumstances should the dose of study drug be
altered due to an adverse event.
4.5.3 Guidelines for Methotrexate
Subjects must enroll on a stable minimum targeted dose of 20 mg/week. Subjec ts may enroll 
with MTX doses < 20 mg/week but 7.5mg/week if intolerance to higher doses has been 
recorded in the source documents. All subjects must be maintained on the enrollment MTX dose, 
unless toxicity  or intolerability  occurs during the course of the study . In that event, the dose may 
be reduced or held as medically  necessary  for adverse events. However , MTX should be returned 
to the baseline dose as soon as possible, or to the maximally  tolerated dose below the baseline 
dose, but not less than 7.5 mg/week for the duration of the study . MTX should be given orall y.
Date: 27-Jul-2015 37
1.0
Approved
930091469
1.0
v

Clinical Protocol IM101567
BMS -188667 abatacept
4.6 Blinding/Unblinding
Double blinding of study drug, adalimumab vis-à- vis abatacept, is not feasible due to logistical 
barriers around re-packaging adalimumab as well as the expected differences in injection site 
reactions. Both of these together make effective blinding of the patients to the randomized drug 
assignment impractical and unsustainable. The nature and frequency  of adalimumab -associated 
injection site reactions make blinding investigators responsible for clinical care unsustainable 
under usual practices. It is possible, however, to preserve the objectivity  of clinical assessments 
with the following strategy  that has been designed to establish and maintain a single -blinded 
assessor for clinical end-points throughout the study .This will require a minimum of 
3individuals: a blinded clinic al assessor, an unblinded Study  Research Coordinator and an 
unblinded phy sician investigator/subinvestigator to complete /approve the CRF.
Clinical Assessors will be blinded to treatment allocation so as to preserve the objectivity  of 
study -related assessme nts (tender and swollen joint count, Physician’s Global Assessment of 
Disease Activity , AE causality  assessment) and routine clinical care (laboratory  result review, 
medication adjustment). To preserve blinding, they must be shielded from treatment allocat ion. 
This will be the responsibility  of the Study /Research Coordinators who need not be blinded to 
treatment allocation. At the beginning of each study  visit throughout the study  duration, the 
subject should be reminded that the Clinical Assessor is blinded to treatment allocation and that 
care must be taken to prevent revealing treatment allocation. They  should be instructed to:
not discuss study  drug by name
not discuss the color or use of the pre -filled sy ringe
not discuss how often injections are performed
only discuss injection site reactions of significant concern .
To comply  with requirements for Case Report Form Completion (CRF) , a qualified physician 
who is an investigator or subinvestigator who is unblinded to study  drug assignment will be 
needed to promptl y review, sign, and date the CRF.
The site should maintain two distinct sets of source documents, one set accessible to the 
unblinded site staff and one set for the blinded Clinical Assessor.
Care should be taken by the Study /Research Coordinator to retrieve any study  drug and sharps 
container returned by the subject at the beginning of each visit to shield the assessor from 
inadvertent exposure to subject allocation. Similarly , study  drug dispensin g should be done after 
blinded assessments. Both retrieval and dispensing of study  drug should be done in an area 
shielded from the blinded assessor(s). 
The joint count assessment should be performed after completion of the patient report outcomes 
(PRO), vital sign assessment, and AE assessment. The Clinical Assessor will similarly  be 
reminded at the beginning of each study  visit throughout the study  duration that they are 
performing a blinded- assessment for the study  and to not ask question or elicit comm ents that 
may reveal treatment allocation as outlined above. Every  effort must be made to ensure the same 
Date: 27-Jul-2015 38
1.0
Approved
930091469
1.0
v

Clinical Protocol IM101567
BMS -188667 abatacept
evaluator(s) will complete the assessment for each subject. If the usual evaluator is not available, 
another trained evaluator blinded to study  drug allocation for the subject may perform the 
clinical assessment. In the event that no blinded evaluator is available during the study  visit, 
blinded clinical assessment measures (tender and swollen joint counts and physician global 
assessment of disease acti vity) should not be reported.
The Sponsor will be unblinded to the treatment assignments of the subject in the trial as it is not 
possible to restrict access to the dosing CRF pages. However, the Sponsor’s medical monitor, 
protocol manager, biomarker repre sentative, and statistician will make every  effort to review 
data in an unbiased fashion. However, theimpact on the study  is believed to be minimal based 
on the primary  objective.
The BMS Bioanaly tical Science Department or its designee will be unblinded to the randomized 
treatment assignments in order to accuratel y perform sample analy sis for the PK and 
immunogenicit y samples.
Unblinding of study  drug allocation for safet y purposes is not necessary  because all study  drug 
provided to the site is open -label ed.
4.7 Treatment Compliance
All subjects are expected to receive study  therapy as outlined in the protocol. Subjects will use 
diary  cards to document self-injection of study drug between clinic visits. Permitted dose 
modifications are described in Section 4.5.Conditions under which therapy must be discontinued 
due to non- compliance are outlined in Section 3.5.
4.8 Destruction of Study  Drug
For this study , study  drugs (those supplied by BMS or sourced by the investigator) such as 
partially  used study  drug containers, vials and s yringes may be destroy ed on site.
Any unused study  drugs can only be destro yed after being inspected and reconciled by the 
responsible Study  Monitor unless study  drug containers must be immediatel y destro yed as 
required for safet y, or to meet local regulations ( eg,cytotoxics or biologics).
On-site destruction is allowed provided the following minimal standards are met:
On-site disposal practices must not expose humans to risks from the drug.
On-site disposal practices and procedures are in agreement with applicable laws and 
regulations, including any  special requirements for controlled or hazardous substances.
Written procedures for on-site disposal are available and followed. The procedures must be 
filed with the site’s SOPs and a cop y provided to BMS upon request.
Records are maintained that allow for traceability  of each container, including the date 
disposed of, quantity  disposed, and identification of the person disposing the containers. The 
method of disposal, ie,incinerator, licensed sanitary  landfill, or licensed waste disposal 
vendor must be documented.
Accountability  and disposal records are complete, up-to-date, and available for the Monitor 
to review throughout the clinical trial period.
Date: 27-Jul-2015 39
1.0
Approved
930091469
1.0
v

Clinical Protocol IM101567
BMS -188667 abatacept
If conditions for destruction cannot be met the responsible Study  Monitor will make 
arrangements for return of study  drug.
It is the investigator’s responsibility  to arrange for disposal of all empty  containers, provided that 
procedures for proper disposal have bee n established according to applicable federal, state, local, 
and institutional guidelines and procedures, and provided that appropriate records of disposal are 
kept.
4.9 Return of Study Drug
If study  drug will not be destro yed upon completion or termination of the study , all unused 
and/or partially  used study  drug that was supplied by BMS must be returned to BMS. The return 
of study  drug will be arranged by  the responsible Study  Monitor. 
It is the investigator’s responsibility  to arrange for disposal of all em pty containers, provided that 
procedures for proper disposal have been established according to applicable federal, state, local, 
and institutional guidelines and procedures, and provided that appropriate records of disposal are 
kept.
Date: 27-Jul-2015 40
1.0
Approved
930091469
1.0
v

Clinical Protocol IM101567
BMS -188667 abatacept
5 STUDY ASSESSMENTS A ND PROCEDURES
5.1 Flow  Chart/Time and Events Schedule 
Table 5.1-1: Flow Chart for Protocol IM101 -567 - Screening Period
ProcedureScreening
VisitaExtended Screening 
VisitbNotes
Eligibility Assessments
Informed Consent X
Inclusion/Exclusion Criteria X X
Medical History X X
Enroll Subject XContact IVRS for subject number. If subject does not meet eligibility 
criteria, contact IVRS to screen fail subject.
Safety Assessments
Physical Examination X X
Height and Weight X
Vital Signs X X Body temperature, seated blood pressure ,and heart rate.
Adverse Events Assessment X X
Prior and Concomitant Medication X X
TB Screening Test XTB testing ( IFN- γ release assay or PPD) performed locally within the 
month prior to Screening will be accepted .A copy of the report must 
be filed in the subject binder. See Section 5.3.5 for important details.
Chest X-ray (CXR) XRequired only if the results of a CXR performed within the 3 months 
prior to enrollment are not available.
Laboratory Tests
Hem atology (CBC) X X
Chemistry X X
Urinalysis X
Date: 27-Jul-2015 41
1.0
Approved
930091469
1.0
v

Clinical Protocol IM101567
BMS -188667 abatacept
Table 5.1-1: Flow Chart for Protocol IM101 -567 - Screening Period
ProcedureScreening
VisitaExtended Screening 
VisitbNotes
HBsAg X If positive, obtain HBV DNA (see Section 5.3.6.4 )
Hepatitis C Antibody X If positive, reflex to HCV confirmation such as PCR
HIV X
Quantitative Immunoglobulins (IgG,
IgA, IgM)X
Urine Pregnancy Test X X WOCBP only; see Section 5.3.6.5 .Performed locally.
ESR X X Performed locally, kits provided centrally.
 
Disease Assessments
Tender (68)/sw ollen (66) Joint Count X X
Subject Global Assessment of Disease 
ActivityXXSee Appendix 5
aThe duration of the screening period should not exceed 28 days .
bSubjects that experience an acute infection or initiate treatment for latent TB may extend the screening period to 42 days. Under these circumstances, all 
screening procedures except subject consenting, IVRS enrollm ent, height/weight, immunoglobulins, urinalysis, anti-CCP 2, RF, chest x-ray, TB testing,
HepB/C and HIV should be repeated prior to randomization.
Date: 27-Jul-2015 42
1.0
Approved
930091469
1.0
v

Clinical Protocol IM101567
BMS -188667 abatacept
Table 5.1-2: Flow Chart for Protocol IM101567 - Treatment Perioda
ProcedureDay 1
(Rand)Week 
4Week 
8Week 12 
(Phone 
Visit)Week 
16Week 20
(Phone 
Visit)Week24/
Early 
Termina
tionNotes
Randomize Subject Using IVRS X
Eligibility Assessments
Inclusion/Exclusion Criteria XRevie w of I/E criteria that are relative 
to the Randomization day
Safety Assessments
Physical Examination X
Vital Signs X X X X XBody  temperature, seated blood 
pressure, and heart rate.
Weight X X
Concomitant Medications X X X X X X X
Adverse Events Assessment X X X X X X XCausality determined by a blinded 
Clinical Assessor
Laboratory Assessments
Hem atology (CBC) X X X X X
Chemistry Panel X X X X X
Urine Pregnancy Test X X X X X X XWOCBP only; see Section 5.3.6.5 .
Performed locally. Pregnancy testing 
also performed prior to dosing at 
Weeks 12 and 20.
MTX polyglutamate X X X X X
ANA and reflex ENA panels X X X X X
Anti-dsDNA X X X X X
Anti-cardiolipin antibodies X X X X X
Date: 27-Jul-2015 43
1.0
Approved
930091469
1.0
v

Clinical Protocol IM101567
BMS -188667 abatacept
Table 5.1-2: Flow Chart for Protocol IM101567 - Treatment Perioda
ProcedureDay 1
(Rand)Week 
4Week 
8Week 12 
(Phone 
Visit)Week 
16Week 20
(Phone 
Visit)Week24/
Early 
Termina
tionNotes
 
 
 
 
 
 
 
 
Date: 27-Jul-2015 44
1.0
Approved
930091469
1.0
v

Clinical Protocol IM101567
BMS -188667 abatacept
Table 5.1-2: Flow Chart for Protocol IM101567 - Treatment Perioda
ProcedureDay 1
(Rand)Week 
4Week 
8Week 12 
(Phone 
Visit)Week 
16Week 20
(Phone 
Visit)Week24/
Early 
Termina
tionNotes
Efficacy Assessment
Tender (68)/sw ollen (66) Joint 
CountX X X X XPerformed by a blinded Clinical 
Assessor
Subject Assessment of Pain X X X X X See Appendix 4
Subject Global Assessment of 
Disease ActivityX X X X X See Appendix 5
Physician Global Assessment of 
Disease ActivityX X X X XPerformed by a blinded Clinical 
Assessor; See Appendix 6
Physical Function (HAQ -DI) X X X X X See Appendix 7
Study Drug Administration
Contact IVRS X X X X XContact is required to randomize the 
subject on Day 1 and to dispense 
medication at each office visit.
Train subjects and/or caregiver on 
how to self-inject and how to fill out 
the diary cardsX
Dispense diary cards X X X X
Collect and review diary cards X X X X
Dispense urine pregnancy kits for 
WOCBP for home use every 
4weeksX XNot applicable if serum pregnancy 
testing is required per local 
regulations.
Date: 27-Jul-2015 45
1.0
Approved
930091469
1.0
v

Clinical Protocol IM101567
BMS -188667 abatacept
Table 5.1-2: Flow Chart for Protocol IM101567 - Treatment Perioda
ProcedureDay 1
(Rand)Week 
4Week 
8Week 12 
(Phone 
Visit)Week 
16Week 20
(Phone 
Visit)Week24/
Early 
Termina
tionNotes
Dispense urine pregnancy kits for 
possible use during Follow -up 
PeriodX See Table 5.1 -3
Dosing of weekly 
abatacept/biw eekly adalimumabX X X X X XMust be administered w eekly 
(abatacept) or biw eekly (adalimumab) 
betw een visits. See Section 4.5
Dispense monthly abatacept or 
adalimumab monthly kitsX X X XTwo monthly kits are dispensed at 
Week 8 and Week 16.
Reconciliation of abatacept or 
adalimumab monthly kitsX X X X
aAll visits and procedures during the Treatment P eriod must occur w ithin 3 days of the expected visit.
bThese samples will only be evaluated to determine serum abatacept or adalimumab concentration in the event there is a corresp onding positive 
immunogenicity result.
Date: 27-Jul-2015 46
1.0
Approved
930091469
1.0
v

Clinical Protocol IM101567
BMS -188667 abatacept
Table 5.1-3: Flow Chart for Protocol IM101567 -Follow -Up Period
Procedure Day 85 after last doseaNotes
Safety Assessments
Vital Signs X Body  temperature, seated blood pressure, and heart rate.
Adverse Events Assessment X
Concomitant Medication Review X
Laboratory Assessments
Urine Pregnancy Test X WOCBP only; see Section 5.3.6.5 . Performed locally. 
aVisit must occur within 10 days of the expected day of the visit. The follow -up visit should ideally be an in-person visit. If this is not possible, a telephone 
follow -up visit will be performed to confirm the results of the urine pregnancy test as well as adverse event and concomitant medication revie w. Vital signs 
will not be collected as part of a telephone follow -up phone visit.
Date: 27-Jul-2015 47
1.0
Approved
930091469
1.0
v

Clinical Protocol IM101567
BMS -188667 abatace pt
5.1.1 Retesting During Screening, Extended Screening, or Rescreening
All screening procedures are to be performed within 4 weeks of the randomization visit except as 
described below.
Retesting:
A single retest of the anti-CCP2, RFand hsCRP within the Screening period will be permitted 
(in addition to any  parameters that require a confirmatory  value).
Any new result will override the previous result (ie, the most current result prior to 
Randomization) and is the value by which study inclusion will be assessed, as it represents the 
subject’s most current, clinical state.
Laboratory  parameters and/or assessments that are included in Table 5.1-1, Screening Period,
may be repeated in an effort to find all possible well-qualified subjects. Consultation with the 
Medical Monitor may be needed to identify  whether repeat testing of any particular parameter is 
clinically  relevant.
Extended Screeni ng:
Subjects that experience an acute infection or initiate treatment for latent TB may extend the 
screening period to 42 days, as long as the infection did not require hospitalization or 
administration of parenteral antibiotics agents. Under these circums tances, all screening 
procedures except IVRS enrollment, height/weight, immunoglobulins, urinaly sis, anti -CCP2, RF, 
chest x -ray, TB testing, HepB/C and HIV should be repeated prior to randomization .
Rescreening:
This study  permits the rescreening of a subject that has discontinued the study  as a pre-treatment 
failure (ie, subject has not been randomized / has not been treated), still meets all 
inclusion/exclusion criteria, and no more than 9months have elapsed prior to enrollment since 
the onset of symptoms of RA. If rescreened , the subject must be re-consented. A subject may be 
rescreened only once. Medical Monitor approval is required and rescreens are not permitted less 
than 28 daysafter signing the first informed consent. The subject will need to sign a new 
informed consent and be reenrolled with a new subject number via the IVRS. Some tests such as 
chest x-ray, may not need to be repeated if they were performed within the protocol defined 
window.
5.1.2 Order of Stu dy Assessments
Study assessments should be performed in the following order:
1)Patient reported outcomes (PROs) questionnaires
2)AE collection
3)Vital signs
4) Joint assessments
5)Investigator assessments
Date: 27-Jul-2015 48
1.0
Approved
930091469
1.0
v

Clinical Protocol IM101567
BMS -188667 abatace pt
6)Blood draws
7)Study  drug administration
5.2 Study Materials
The following materials will be provided for use during the trial:
Diary  cards to record SC dosing administration and the monthly  pregnancy  test results for 
WOCBPs (mandatory )
Written instructions on how to use the SC sy ringes
eCRF instructions
Pregnancy  Surve illance Forms
Subject and Investigator -rated questionnaires/scales (paper)
Drug Inventory  binder (optional)
Interactive Voice Response System (IVRS) worksheets
Laboratory  test kits for all required laboratory  testing
Cooler bags and gel packs will be provi ded to assist subjects in transporting stud y drug
Sharps containers will be provided to assist subjects in disposing of used SC sy ringes
Tote bags to transport cooler bags, sharp containers and study  drug
For WOCBP urine pregnancy  kits/instructions will beprovided to be used between office 
visits.
5.3 Safety  Assessments
On Day 1, the results of all assessments must be reviewed to assure that eligibility  requirements 
are met before contacting the Central Randomization System for the subject’s randomization 
assignment.
Subjects who terminate treatment early should complete the appropriate Early  Termination Visit 
and the Post Drug Follow -up Visits. The Early  Termination Visit should be as soon as possible 
after the last dose of study  medication.
All assessments should be performed or administered prior to study  drug administration unless 
otherwise indicated.
Only  data for the procedures and assessments specified in this protocol should be submitted to 
BMS on a case report form. Additional procedures and assessment s may be performed as part of 
standard of care; however, data for these assessments should remain in the subject’s medical 
record and should not be provided to BMS, unless specificall y requested from BMS.
Date: 27-Jul-2015 49
1.0
Approved
930091469
1.0
v

Clinical Protocol IM101567
BMS -188667 abatace pt
5.3.1 Physical Examination
Physical examinations may be performed by a Doctor of Medicine (MD), Doctor of Osteopath y 
(DO), Ph ysician Assistant (PA), or Nurse Practitioner (NP).
The physical examination should include examination of the heart, lungs, abdomen, the lymph 
nodes, liver, spleen and skin. A physical examination may note any changes in the subject’s 
condition (body  systems) since the last assessment and does not preclude examination of any 
other bod y systems as clinically  indicated.
5.3.2 Chest X -ray
A posterior -anterior and lateral chest x-ray, performed during screening, is required for all 
subjects unless performed within 3 months prior to obtaining written informed consent and 
documentation of the earlier x-ray is on file. Investigators must ensure that the results of the 
chest x-ray satisfy  criteria for eligibility . The chest x-ray result will be recorded on the 
appropriate page of the eCRF.
5.3.3 Physical Measurements
Weight and height is to be recorded at screening. Weight will also be recorded at Day 1  and 
Week 24/Earl y Termination.
5.3.4 Vital Signs
Vital signs (seated blood pressure, heart rate, and temperature) will be recorded during every  
office visit and prior to dose administration, when applicable. Blood pressure and heart rate 
should be measured after the subject has been seated quietly  for at least 5 min utes.
5.3.5 TB Screening
Chest x-ray,history , and physical examination are considered part of the process to assess a 
subject’s eligibility . In addition to a chest x-ray that does not show any evidence or suspicion of 
latent TB, a tuberculin skin testwill be performed and interpreted according to local country 
Health Authorities and/or Medical Society  guidelines. Some guidelines have specific 
recommendations for subjects who are to receive biologics or immunosuppressant therapies 
(eg,RA experience with biologic agents),27,28,29or who are immunocompromised and who have 
had prior BCG vaccination(s).30,31Tuberculin skin testing is not contraindicated for persons who 
have been vaccinated with BCG. An interferon gamma release assay  (eg, QuantiFERONGold 
or Tspot/ELISpot) is an acceptable alternative when skin testing for tuberculosis (ie, PPD) is not 
appropriate.
5.3.6 Laboratory Assessments
All laboratory  assessments will be analy zed centrally  except if noted otherwise .
Date: 27-Jul-2015 50
1.0
Approved
930091469
1.0
v

Clinical Protocol IM101567
BMS -188667 abatace pt
Blood samples will be obtained at all visits noted inTime and Events Schedule . Any laboratory  
test result that the investigator considers clinicall y relevant should be recorded on the appropriate 
Adverse Event page of the CRF (see Appendix 8).
5.3.6.1 Hematology
Hemoglobin
Hematocrit
Total WBC count, inclu ding differential
Platelet count
5.3.6.2 Blood Chemistry
Sodium Creatinine
Potassium Blood urea nitrogen (BUN)
Chloride Total bilirubin
Total Protein Alanine aminotransferase (ALT)
Albumin Aspartate aminotransferase (AST)
Calcium Gamma -glutam yltransferase (GGT)
Phosphorus Alkaline phosphatase
Glucose hsCRP
Rheumatoid Factor ANA and reflex ENA panels
MTX poly glutamate ESR*
Quantitative I mmunoglubulins (IgG, IgA, IgM)
*Performed locally , kits provided centrally .
5.3.6.3 Urinalysis 
pH
Protein
Glucose
Blood
5.3.6.4 Hepatitis Screen 
The Laboratory  result smust be available on Day  1 prior to dosing.
Hepatitis B surface antigen, hepatitis B core antibody . If positive ,reflex HBV DNA testing 
must be performed.
Hepatitis C antibody . If positive, reflex HCV RNA testing must be performed
Date: 27-Jul-2015 51
1.0
Approved
930091469
1.0
v

Clinical Protocol IM101567
BMS -188667 abatace pt
5.3.6.5 Pregnancy Tests
Urine/serum pregnancy  tests (minimum sensitivity  25 IU/L of -HCG) must be performed for all 
WOCBP within 24 hours prior to dosing for visits specified in Section 5.1. A serum test must be 
performed for confirmation of any positive urine test result. Urine tests can be processed locall y 
and can be self-administered by the subject between office visits, if permitted by local 
regulations. If any female subject becomes pregnant, she will stop receiving study  treatment 
immediately  and enter the Post Treatment Follow -up Period . A pregnancy  surveillance form will 
be completed and submitted to Bristol -Myers Squibb. Serum pregnancy  tests will be processed 
centrall y.
5.3.6.6 HIV Testing
HIV testing will be performed for all subjects.
5.4 Efficacy  Assessments
Questionnaires and investigator/subject assessments will be completed prior to study  drug 
administration. 
Physicians Global Assessment
The Physicians Global Assessment of Disease Activity  (PGA) can be performed by the
investigator or sub-investigator. The sub-investigator may be a Doctor of Medicine (MD) or 
Doctor of Osteopath y (DO).
Joint Count Assessments
The Joint Count Assessor may perform the PGA for the same subject . For both assessments 
every  effort should be made to ensure the same assessor is used for a given subject throughout 
the study . 
Training and instruction on joint count assessments will be discussed at the Investigator’s 
Meeting or at other trainings and workshops. Any assessors at a site who were not trained by a 
centralized BMS trainer should receive instruction by their site primary  assessor who has 
undergone the centralized BMS training. The secondary  assessor may conduct joint counts for 
the trial only after having performed satisfa ctorily  at least 3 patient assessments under the 
supervision of the primary  assessor. Additional information related to joint assessor training will 
be provided b y BMS or a delegate.
Joint Count Assessors should have appropriate medical credentials and/or should be individuals 
with appropriate scientific/medical background who are experienced in performing joint 
assessments for the BMS Phase 3 RA studies. If the individual does not have medical 
credentials, documentation of their experience (preferabl y on a curriculum vitae) must be 
provided to the BMS site manager, and their eligibility  as joint assessor must be confirmed by 
the BMS medical monitor before the individual’s participation in the study  as joint assessor.
Date: 27-Jul-2015 52
1.0
Approved
930091469
1.0
v

Clinical Protocol IM101567
BMS -188667 abatace pt
Visits should be scheduled with the availability  of the assessor taken into account. If the assessor 
is unable to complete the evaluation, then another qualified individual can take the place of the 
initial evaluator, as long as the restrictions, described above, are still met. The substitute 
evaluator will have also examined and reviewed the subject with the initial assessor to ensure 
consistency  between subject evaluations.
Patient Reported Outcomes
Subjects will complete the Global Assessment of Disease Activity  (VAS), HAQ- DI, and 
Assessment of Pain (VAS). 
5.4.1 Imaging Assessment for the Study
Not Applicable.
 
 
 
 
 
 
 
 
 
Date: 27-Jul-2015 53
1.0
Approved
930091469
1.0
v

Clinical Protocol IM101567
BMS -188667 abatace pt
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Date: 27-Jul-2015 54
1.0
Approved
930091469
1.0
v

Clinical Protocol IM101567
BMS -188667 abatace pt
 
 
 
 
 
 
5.7 Outcomes Research A ssessments
The following assessments will be performed: 
a)Subject Assessment of Pain: Pain reported bypatients, measured on 10 cm VAS. See 
Appendix 4.
b) Subject Assessment of Physical Functioning: The Health Assessment Questionnaire 
(HAQ), published in 1980, is one of the most widely  used, comprehensive, validated, 
patient -oriented outcome assessment instruments available. HAQ disability  index takes 
into account the subject’s use of aids, devices, or assistance in the scoring algorithm for a 
disability  category . See Appendix 8.
c)Subject Assessment of Disease Activity : Global disease assessment of disease activity  by 
patients measured on 10 cm VAS. See Appendix 5.
 
 
 
 
 
 
Date: 27-Jul-2015 55
1.0
Approved
930091469
1.0
v

Clinical Protocol IM101567
BMS -188667 abatace pt
 
 
6 ADVERSE EVENTS
An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a 
preexisting medical condition in aclinical investigation subject administered study  drugand that 
does notnecessarily  have a causal relationship with this treatment. An AE can therefore be any 
unfavorable and unint ended sign (such asan abnormal laboratory  finding ), sympto m, or disease 
temporally  associated with the use of study  drug, whether or not considered related to the study 
drug.
The causal relationship to study  drug is determined by a physician and should be used to assess 
all adverse events (AE). The ca usal relationship can be one of the following:
Related: There is a reasonable causal relationship between study  drug administration and 
the AE.
Not related: There is not a reasonable causal relationship between study  drug 
administration and the AE.
The term "reasonable causal relationship" means there is evidence to suggest a causal 
relationship.
Adverse events can be spontaneously  reported or elicited during open -ended questioning, 
examination, or evaluation of a subject. (In order to prevent reporting bias, subjects should not be 
questioned regarding the specific occurrence of one or more AEs.)
6.1 Serious A dverse Events
A Serious Adverse Event (SAE) is any  untoward medical occurrence that at any dose: 
results in death
is life -threatening (defined as an event in which the subject was at risk of death at the time of 
the event; it does not refer to an event which hypothetically  might have caused death if it 
were more severe)
requires inpatient hospitalization or causes prolongation of existing hospitalization 
(seeNOTE below)
results in persistent or significant disability /incapacity
is a congenital anomal y/birth defect 
is an important medical event (defined as a medical event(s) that may not be immediatel y 
life-threatening or result in death or hospitalization but, based upon appropriate medical and 
scientific judgment, may jeopardize the subject or may require intervention [eg, medical, 
surgical] to prevent one of the other serious outcomes listed in the definition above.)
Date: 27-Jul-2015 56
1.0
Approved
930091469
1.0
v

Clinical Protocol IM101567
BMS -188667 abatace pt
Examples of such events include, but are not limited to, intensive treatment in an emergency 
room or at home for allergic bronchospasm; blood dyscrasias or convulsions that do not 
result in hospitalization.) Potential drug induced liver injury  (DILI) is also considered an 
important medical event. (See Section 6.6for the definition of potential DILI.)
Suspected transmission of an infectious agent (eg, pathogenic or nonpathogenic) via the study  
drug is an SAE.
Although pregnanc y,overdose , cancer ,and potential drug induced liver injury  (DILI) are not 
alway s serious by regulatory  definition, these events must be handled asSAEs.
(See Section 6.1.1 for reporting pregnancies).
Any component of a study  endpoint that is consider ed related to study  therap y (eg,death is an 
endpoint, if death occurred d ue to anaphy laxis, anaphy laxis must be reported) should be reported 
as SAE (see Section 6.1.1 for reporting details ).
NOTE : 
The following hospitalizations arenot considered SAEs in BMS clinical studies:
a visit to the emergency room or other hospital department < 24 hours, that does not 
result in admission (unless considered an important medical or life- threatening event)
elective surgery , planned prior to signing consent
admissions as per protocol for a planned medical/surgical procedure
routine health assessment requiring admission for baseline/trending of health status 
(eg,routine colonoscop y)
medical/surgical admission other than to remedy  ill health and planned prior to entry  into 
the study . Appropri ate documentation is required in these cases
admission encountered for another life circumstance that carries no bearing on health 
status and requires no medical/surgical intervention (eg, lack of housing, economic 
inadequacy , caregiver respite, family  circumstances, administrative reason ).
Admission for administration of anticancer therapy  in the absence of any other SAEs 
(applies to oncology protocols)
6.1.1 Serious Adverse Event Collection and Reporting
Sections 5.5.1 in the Investigator Brochure (IB) represent the Reference Safety  Information to 
determine expectedness of serious adverse events for expedited reporting . Following the 
subject’s written consent to participate in the study , all SAEs, whether related or not related to 
study  drug, must be collected, including those thought to be associated with protocol -specified 
procedures .All SAEs must be collected that occur during the screening period and within
85daysof discontinuation of the Treatment Period . If applicable, SAEs must be collected that 
relate to an y later protocol -specified procedure ( eg, a follow -up skin biopsy ). 
Date: 27-Jul-2015 57
1.0
Approved
930091469
1.0
v

Clinical Protocol IM101567
BMS -188667 abatace pt
The investigator must report any SAE that occurs after these time periods and that is believed to 
be related to stud y drug or protocol -specified procedure. 
An SAE report must be completed for an y event where doubt exists regarding its seriousness. 
If the investigator believes that an SAE is not related to study  drug, but is potentially  related to 
the conditions of the study  (such as withdrawal of previous thera py or a complication of a study  
procedure), the relationship must be specified in the narrative section of the SAE Report Form.
SAEs, whether related or not related to study  drug, and pregnancies must be reported to BMS 
(ordesignee) within 24 hours of awareness of the even t. SAEs must be recorded on the SAE 
Report Form; pregnancies on a Pregnancy  Surveillance Form (electronic or paper forms). The 
preferred method for SAE data reporting collection is through the eCRF. The paper 
SAE/pregnancy  surveillance fo rms are only  intended as a back -up option when the eCRF system 
is not functioning. In this case, the paper forms are to be transmitted via email or confirmed 
facsimile (fax) transmission to:
SAE Email Address: Refer to Contact Information list.
SAE Facsimile Number :Refer to Contact Information list.
For studies capturing SAEs through electronic data capture (EDC), electronic submission is the 
required method for reporting. In the event the electronic system is unavailable for transmission, 
paper forms must be used and submitted immediately .When paper forms are used, the original 
paper forms are to remain on site.
SAE Telephone Contact (required forSAE and pregnancy  reporting) :Refer to Contact
Information list.
If only  limited information is initially  available, follow -up reports are required. (Note: Follow -up 
SAE reports must include the same investigator term(s) initially  reported.) 
If an ongoing SAE changes in its intensity  or relationship to study  drug or ifnew information 
becomes available, the SAE report must be updated and submitted within 24 hours to BMS 
(ordesignee) using the same procedure used for transmitting the initial SAE report.
All SAEs must be followed to resolution or stabilization.
6.2 Nonseriou s Adverse Events
Anonserious adverse event is an AE not classified as serious.
6.2.1 Nonserious Adverse Event Collection and Reporting
The collection of non serious AE information should begin at initiation of study  drug. Non serious 
AEinformation should also becollected from the start of a placebo lead-in period or other 
observational period intended to establish a baseline status for the subjects.
Nonserious AEs should be followed to resolution or stabilization, or reported as SAEs if they 
become serious (see Section 6.1.1). Follow -up is also required for nonserious AEs that cause 
interruption or discontinuation of study  drug andfor those present at the end of study  treatment 
Date: 27-Jul-2015 58
1.0
Approved
930091469
1.0
v

Clinical Protocol IM101567
BMS -188667 abatace pt
as appropriate. All identified nonserious AEs must be recorded and described on the nonserious 
AE page of the CRF (paper or electronic). 
Completion of supplemental CRFs may be requested for AEs and/or laboratory  abnormalities 
that are reported/identified during the cours e of the study .
6.3 Laboratory  Test Result Abnormalities
The following laboratory test result abnormalities should be captured on the nonserious AE CRF 
page or SAE Report Form (paper or electronic) as appropriate:
Any laboratory  test result that is clinically  significant or meets the definition of an SAE
Any laboratory test result abnormality  that required the subject to have study  drug 
discontinued or interrupted
Any laboratory test result abnormality  that required the subject to receive specific corrective 
therap y
It is expected that wherever possible, the clinical rather than laboratory  term would be used by 
the reporting investigator ( eg, anemia versus low hemoglobin value).
6.4 Pregnancy
If, following initiation of the study  drug, it is subsequently  discovered that a study  subject is 
pregnant or may have been pregnant at the time of study expos ure, including during at least 5
half lives after product administration, the investigator must immediately  notify  the BMS 
Medical Monitor/designee of this event and complete and forward a Pregnancy  Surveillance 
Form to BMS Designee within 24 hours of awareness of the event and in accordance with SAE 
reporting procedures described in Section 6.1.1.
In most cases, the study  drug will be permanently  discontinued in an appropriate manner 
(eg,dose tapering if necessary  for subject safet y).
In the rare event that the benefit of continuing study  drug is thought to outweigh the risk, after 
consultation with BMS, the pregnant subject may continue study  drug after a thorough 
discussion of benefits and risk with the subject .
Protocol -required procedures for study  discontinuation and follow -up must be performed on the 
subject unless contraindicated by pregnancy  (eg, x-ray studies). Other appropriate pregnancy 
follow -up procedures should be considered if indicated.
The investigator must immediately  notify  the BMS (or designee) Medical Monitor of this event 
and complete and forward a Pregnancy  Surveillance Form to BMS (or designee) within 24 hours 
of awareness of the event and in accordance with SAE reporting procedures described in 
Section 6.1.1.
Follow -up information regarding the course of the pregnancy , including perinatal and neonatal 
outcome and, where applica ble, offspring information must be reported on the Pregnancy 
Surveillance Form.
Date: 27-Jul-2015 59
1.0
Approved
930091469
1.0
v

Clinical Protocol IM101567
BMS -188667 abatace pt
Any pregnancy  that occurs in a female partner of a male study  participant should be reported to 
BMS . Information on this pregnancy  will be collected on the Pregnancy  Surveillan ce Form.
6.5 Overdose
An overdose is defined as the accidental or intentional administration of any dose of a product 
that is considered both excessive and medically  important. All occurrences of overdose must be 
reported as an SAE (see Section 6.1.1 for repor ting details.).
6.6 Potential Drug Induced Liver Injur y (DILI)
Specific criteria for identify ing potential DILI have not been identified for this protocol. 
Standard medical practice in identify ing and monitoring hepatic issues should be followed.
6.7 Other Safety  Considerations
Any significant worsening noted during interim or final physical examinations, 
electrocardiogram, x-ray filming ,any other potential safet y assessment required or not required 
by protocol should also be recorded as a nonserious or serious AE, as appropriate, and reported 
accordingl y. 
7 DATA MONITORING COMM ITTEE A ND OTHER EXTE RNA L 
COMMITTEES
Not applicable
8 STATISTICA L CONSIDERA TIONS
8.1 Sample Size Determination
In this stud y 25 subjects will be randomized per treatment arm.
This is anexploratory  study with only exploratory  objectives. No formal sample size and power 
calculation will be provided. It should be noted that with 25subjects per arm the half width of 
the 95% CI for differences in proportion (eg, proportion of seroconversion for anti-CCP2, 
ACPA) will range from 25 to 30%. This means that only  if the treatment difference in proportion 
is larger than 25-30% the difference will be declared statisticall y significant at 5% significance 
level. For changes from baseline in continuous variables the minimal detectable effect size 
(treatment difference in changes divided by common standard deviation) to declare statistical 
significance (with 5 % significance level) is 0.57. 
The population will be enriched to allow for assessment of important changes in the immune 
phenoty pe by  including only  subjects who are anti -CPP2 positive.
8.2 Populations for A nalyses
The as-treated analysis population will contain all subjects who received at least 1 dose of study 
medication. The treatment that is received will be used in the analy sis.This population will be 
used for all analy ses, including demography , biomarker, efficacy  and safet y anal yses.
Date: 27-Jul-2015 60
1.0
Approved
930091469
1.0
v

Clinical Protocol IM101567
BMS -188667 abatace pt
8.3 Endpoint s
8.3.1 Primary Endpoint(s)
No primary  endpoints are defined for this protocol.
8.3.2 Secondary Endpoint(s)
No seco ndary  endpoints are defined for this protocol.
 
 
 
 
 
 
 
 
 
 
8.4 Analyses
8.4.1 Demographics and Baseline Characteristics
Summary  statistics of all demographics and baseline characteristics will be provided by 
treatment group using the as- treated anal ysis population.
 
 
 
 
 
 
Date: 27-Jul-2015 61
1.0
Approved
930091469
1.0
v

Clinical Protocol IM101567
BMS -188667 abatace pt
8.4.3 Safety Analyses
The evaluation of drug safety  is primaril y based on clinical adverse events and laboratory  
abnormalities reported during the stud y.
Frequency  distributions and listings of all adverse events, deaths, serious adverse events, events 
leading to discontinuation and adverse events of special interest will be generated. Adverse 
events of special interest are infections, malignancies, autoimmune disorders andinjection site 
reactions.
Laboratory  marked abnormalities, using pre-defined abnormalit y criteria, will also be 
descriptivel y summarized.
8.4.4 Pharmacokinetic A nalyses
Not Applicable.
 
 
 
 
 
 
8.4.6 Outcomes Research Analyses
Not applicable
8.4.7 Other Analyses 
Not applicable
8.5 Interim A nalyses
Not applicable
Date: 27-Jul-2015 62
1.0
Approved
930091469
1.0
v

Clinical Protocol IM101567
BMS -188667 abatace pt
9 STUDY MA NAGEMENT
9.1 Compliance
9.1.1 Compliance with the Protocol and Protocol Revisions
The study  shall be conducted as described in this approved protocol. All revisions to the protocol 
must be discussed with, and be prepared by, BMS. The investigator should not implement any 
deviation or change to the protocol without prior review and documented approval/favorable 
opinion from the IRB/IEC of an amendment, except where necessary  to eliminate an immediate 
hazard(s) to stud y subjects. 
If a deviation or change to a protocol is implemented to eliminate an immediate hazard(s) prior 
to obtaining IRB/IEC approval/favorable opinion, as soon as possible the deviation or change 
will be submitted to:
IRB/IEC for review and approval/favorable opinion
BMS
Regulatory  Authority (ies), if required by  local regulations
Documentation of approval signed by the chairperson or designee of the IRB(s)/IEC(s) must be 
sent to BMS.
If an amendment substantially  alters the study  design or increases the potential risk to the 
subject: (1) the consent form must be revised and submitted to the IRB(s)/IEC(s) for review and 
approval/favorable opinion; (2) the revised form must be used to obtain consent from subjects 
currentl y enrolled in the study  if they  are affected by  the amendment; and (3) the new form must 
be used to obtain consent from new subjects prior to enrollment.
If the revision is done via an administrative letter, investigators must inform their I RB(s)/IEC(s).
9.1.2 Monitoring
BMS representatives will review data centrally to identify  potential issues to determine a 
schedule of on -site visits for targeted review of study  records.
Representatives of BMS must be allowed to visit all study  site locations periodically  to assess the 
data qualit y and study  integrit y. On site they will review study  records and directl y compare 
them with source documents, discuss the conduct of the study  with the investigator, and verify 
that the facilities remain acceptable.
In addition, the study  may be evaluated by BMS internal auditors and government inspectors 
who must be allowed access to CRFs, source documents, other study  files, and study  facilities. 
BMS audit reports will be kept confidential.
The investigator must notify  BMS promptly  of any inspections scheduled by regulatory 
authorities, and promptly forward copies of inspection reports to BMS.
Date: 27-Jul-2015 63
1.0
Approved
930091469
1.0
v

Clinical Protocol IM101567
BMS -188667 abatace pt
9.1.2.1 Source Documentation
The Investigator is responsible for ensuring that the source data are accurate, legible, 
contemporaneous, original and attributable, whether the data are hand -written on paper or 
entered electronically . If source data are created (first entered), modified, maintained, archived, 
retrieved, or transmitted electronicall y via computerized systems (and/or any other kind of 
electr onic devices) as part of regulated clinical trial activities, such systems must be compliant 
with all applicable laws and regulations governing use of electronic records and/or electronic 
signatures. Such systems may include, but are not limited to, electr onic medical/health records 
(EMRs/EHRs), adverse event tracking/reporting, protocol required assessments, and/or drug 
accountability  records).
When paper records from such systems are used in place of electronic format to perform 
regulated activities, such paper records should be certified copies. A certified copy consists of a 
copy  of original information that has been verified, as indicated by a dated signature, as an exact 
copy  having all of the same attributes and information as the original.
9.1.3 Investigat ional Site Training
Bristol -Myers Squibb will provide quality  investigational staff training prior to study  initiation. 
Training topics will include but are not limited to: GCP, AE reporting, study  details and 
procedure, electronic CRFs, study documentation, informed consent, and enrollment of WOCBP.
9.2 Records
9.2.1 Records Retention
The investigator must retain all study  records and source documents for the maximum period 
required by applicable regulations and guidelines, or institution procedures, or for the period 
specified by BMS, which ever is longer. The investigator must contact BMS prior to destroy ing 
any records associated with the study .
BMS will notify  the investigator when the study  records are no longer needed.
If the investigator withdraws from the study  (eg, relocation, retirement), the records shall be 
transferred to a mutually agree d upon designee (eg, another investigator, IRB). Notice of such 
transfer will be given in writing to BMS.
9.2.2 Study Drug R ecords 
It is the responsibility  of the investigator to ensure that a current disposition record of study  drug 
(inventoried and dispensed) is maintained at thestudy  site to include investigational product .
Records or logs must comply  with applicable regulations a nd guidelines and should include:
amount received and placed in storage area
amount currentl y in storage area
label identification number or batch number 
amount dispensed to and returned b y each subject, including unique subject identifiers
Date: 27-Jul-2015 64
1.0
Approved
930091469
1.0
v

Clinical Protocol IM101567
BMS -188667 abatace pt
amount transferred to another area /site for dispensing or storage
nonstudy  dispositio n (eg, lost, wasted)
amount destroy ed at study  site, if applicable
amount returned to BMS
retain samples for bioavailability /bioequivalence, if applicable
dates and initials of person responsible for Investigational Product dispensing/accountability , 
as per the Delegation of Authority  Form
BMS will provide forms to facilitate inventory  control ifthe investigational site does not have an 
established sy stem that meets these requi rements.
9.2.3 Case Report Form s
An investigator is required to prepare and maintain adequate and accurate case histories designed 
to record all observations and other data pertinent to the investigation on each individual treated 
or entered as a control in the investigation. Data that are derived from source documents and 
reported on the CRF must be consistent with the source documents or the discrepancies must be 
explained. Additional clinical information may be collected and analyzed in an effort to enhance 
understanding of product safet y. CRFs may  be requested for AEs and/or laboratory  abnormalities 
that are reported or identified during the course of the study .
For sites using the BMS electronic data capture tool, electronic CRFs will be prepared for all 
data collection fields except for fields specific to SAEs and pregnancy , which will be reported on 
the paper or electronic SAE form and Pregnancy  Surveillance form, respectively . Spaces may  be 
left blank only in those circumstances permitted by study-specific CRF completion guidelines 
provided b y BMS . 
The confidentiality  of records that could identify  subjects must be protected, respecting the 
privacy  and confidentiality  rules in accordance with the applicable regulatory  requirement(s).
The investigator will maintain a signature sheet to document signatures and initials of all persons 
authorized to make entries and/or corrections on CRFs. 
The completed CRF ,including any paper or electronic SAE /pregnancy CRFs ,must be promptl y 
reviewed, signed, and dated by the investigator or qualified physician who is a subinvestigator
and who is delegated this task on the Delegation of Authority  Form. For electronic CRFs, review 
and approval/signature is completed electronicall y through the BMS electronic data capture tool.
The investigator must retain a copy of the CRFs including records of the changes and 
corrections.
Each individual electronically  signing electronic CRFs must meet BMS training requirements 
and must only access the BMS electronic data capture tool using theunique user account 
provided b y BMS . User accounts are not to be shared or reassigned to other individuals.
Date: 27-Jul-2015 65
1.0
Approved
930091469
1.0
v

Clinical Protocol IM101567
BMS -188667 abatace pt
9.3 Clinical Study  Report and Publications
A Signatory  Investigator must be selected to sign the clinical study  report. 
For this protocol, the Signatory  Investigator will be selected as appropriate based onthe 
following criteria:
External Principal I nvestigator designated at protocol development
National Coordinating Investigator 
Study  Steering Committee chair or their designee
Subject recruitment ( eg, among the top quartile of enrollers)
Involvement in trial design
Regional representation (eg, among top quartile of enrollers from a specified region or 
country )
Other criteria (as determined by  the study  team)
The data collected during this study  are confidential and proprietary  to BMS. Any publications 
or abstracts arising from this study  must adhere to the publication requirements set forth in the 
clinical trial agreement (CTA) governing [Study  site or Investigator] participation in the study . 
These requirements include, but are not limited to, submitting proposed publications to BMS at 
the earliest practicable time prior to submission or presentation and otherwise within the time 
period set forth in the CTA.
Date: 27-Jul-2015 66
1.0
Approved
930091469
1.0
v

Clinical Protocol IM101567
BMS -188667 abatace pt
10 GLOSSA RY OF TERMS
Term Definition
Com plete Abstinence If one form of contraception is required, Complete Abstinence is defined as complete 
avoidance of heterosexual intercourse and is an acceptable form of contraception for all 
study drugs. Female subjects must continue to have pregnancy tests. Acceptable 
alternate methods of highly effective contraception must be discussed in the event that 
the subject chooses to forego complete abstinence.
If tw o forms of contraception is required, Complete abstinence is defined as complete 
avoidance of heterosex ual intercourse and is an acceptable form of contraception for all 
study drugs. Subjects who choose complete abstinence are not required to use a second 
method of contraception, but female subjects must continue to have pregnancy tests. 
Acceptable alternat e methods of highly effective contraception must be discussed in the 
event that the subject chooses to forego complete abstinence.
Expanded definition Com plete abstinence as defined as complete avoidance of 
heterosexual intercourse is an acceptable form of contraception for all study drugs. This 
also means that abstinence is the preferred and usual lifestyle of the patient. This does 
not mean periodic abstinence (eg, calendar, ovulation, symptothermal, profession of 
abstinence for entry into a clinical trial, post -ovulation methods) and w ithdraw al, which 
are not acceptable methods of contraception. Subjects who choose complete abstinence 
are not required to use a second method of contraception, but female subjects must 
continue to have pregnancy tests. Acceptable alternate methods of highly effective 
contraception must be discussed in the event that the subject chooses to forego complete 
abstinence .
Date: 27-Jul-2015 67
1.0
Approved
930091469
1.0
v

Clinical Protocol IM101567
BMS -188667 abatace pt
11 LIST OF A BBREVIA TION S
Term Definition
ABA abatacept
ACPA anti-citrullinated protein antibody
ACR American College of Rheumatology
ADA adalimumab
AE adverse event
ALT alanine aminotransferase
ANA anti-nuclear antibod y
ANC absolute neutrophil count
anti-CCP anti-cyclic citrullinated peptide
anti-CCP2 commerciall y available test for ACPA
AST aspartate aminotransferase
AT aminotransaminases
AUC area under the time -concentration curve
-HCG beta-human chorionic gonadotrophin
BMS Bristol -Myers Squibb
BP blood pressure
BUN blood urea nitrogen
C Celsius
CBC complete blood count
CFR Code of Federal Regulations 
cm centimeter
CRF Case Report Form, paper or electronic
CRP C-reactive protein
DIP distal interphalangeal
dL deciliter
DMARD disease -modify ing anti-rheumatic drug
dsDNA double -stranded DNA
DSM I V Diagnostic and Statistical Manual of Mental Disorders (4th Edition)
ECG electrocardiogram
Date: 27-Jul-2015 68
1.0
Approved
930091469
1.0
v

Clinical Protocol IM101567
BMS -188667 abatace pt
Term Definition
eCRF Electronic Case Report Form
EDC Electronic Data Capture
eg exempli gratia (for example)
ENA extractable nuclear antigen
ESR Erythrocy te Sedimentation Rate
ET early termination
EU European Union
EULAR European League Against Rheumatism
F Fahrenheit
FDA Food and Drug Administration
FSH follicle stimulating hormone
g gram
GCP Good Clinical Practice
GGT gamma -glutamy l transferase
h hour
HBcAb Hepatitis B core antibody
HBsAg hepatitis B surface antigen
HBV hepatitis B virus
HCV hepatitis C virus
Hgb hemoglobin
HIV Human Immunodeficiency  Virus
HR heart rate
HRT hormone replacement therap y
hsCRP high-sensitivity  C-reactive protein
ICD International Classification of Diseases
ICH International Conference on Harmonisation 
ie id est (that is)
IEC Independent Ethics Committee
IM intramuscular
IMP investigational medicinal products
Date: 27-Jul-2015 69
1.0
Approved
930091469
1.0
v

Clinical Protocol IM101567
BMS -188667 abatace pt
Term Definition
IND Investigational New Drug
IP investigational product
IRB Institutional Review Board
IU International Unit
IV intravenous
kg kilogram
L liter
LDH lactate deh ydrogenase
mg milligram
MHC major histocompatibility  complex
min minute
mL milliliter
mmHg millimeters of mercury
MRHD maximum recommended human dose
MTD maximum tolerated dose
MTX methotrexate
g microgram
N number of subjects or observations
N/A not applicable
NIMP non-investigational medicinal products 
NP nurse p ractitioner
NSAID nonsteroidal anti-inflammatory  drug
NYHA New York Heart Association
PA physician assistant
PBMC Peripheral blood mononuclear cell
PGA Physicians Global Assessment of Disease Activity
PO per os (b y mouth route of administration)
PT prothrombin time
QC quality  control
QD, qd quaque die, once dail y
Date: 27-Jul-2015 70
1.0
Approved
930091469
1.0
v

Clinical Protocol IM101567
BMS -188667 abatace pt
Term Definition
RA rheumatoid arthritis
RBC red blood cell
RF Rheumatoid factor
SAE serious adverse event
SC subcutaneous
SD standard deviation
SLE systemic lupus ery thematosus
SOP Standard Operating Procedures
Subj subject
t temperature
T time
TAO Trial Access Online, the BMS implementation of an EDC capability
TB tuberculosis
TNF tumor necrosis factor 
WBC white blood cell
US United States
WHO World Health Organization
WOCBP women of childbearing potential
Date: 27-Jul-2015 71
1.0
Approved
930091469
1.0
v
